Recent developments highlight strong Q2 2026 financial performance with revenue growth, profit increase, and raised sales guidance for INGREZZA. The company is expanding its sales force and portfolio, with ongoing late-stage clinical programs advancing.

• Neurocrine reported a 39% increase in Q2 revenue and raised FY26 INGREZZA sales guidance [N4].
• Q2 2026 earnings call emphasized portfolio expansion driving growth [N2].
• Q2 profit climbed, reflecting operational performance improvements [N8].
• The company is expanding its INGREZZA and CRENESSITY sales teams to enhance commercial momentum [N2].
• Late-stage clinical programs in major depressive disorder and schizophrenia are progressing with Phase 3 studies underway [N2].

The company has established commercial success with INGREZZA and CRENESSITY, generating significant sales and expanding its sales force to enhance market penetration. Its robust pipeline includes late-stage candidates in major depressive disorder and schizophrenia, with potential to address large unmet needs. Early-stage programs targeting novel mechanisms and modalities may provide future therapeutic options. The company's strategy to launch approximately one new medicine every two years reflects a commitment to innovation. Strong liquidity and profitability in recent quarters support operational stability [S1][S2][N2][N4].

Risks include dependence on a limited number of commercial products for revenue, potential challenges in clinical development and regulatory approval of pipeline candidates, and reliance on third-party manufacturers which may affect supply continuity. The competitive landscape in neuroscience and endocrinology is intense, with pricing pressures and alternative therapies. Expansion of the sales force and infrastructure entails increased costs. Market risks and uncertainties could impact financial performance and stock price [S1][S2].

Neurocrine Biosciences' moat is supported by its FDA-approved, first-in-class and best-in-class products addressing under-served neurological and endocrine disorders, including INGREZZA and CRENESSITY. The company leverages specialized commercial infrastructure and a focused distribution network to manage product supply and patient access. Its diversified and innovative pipeline across multiple therapeutic areas, combined with proprietary platforms and exclusive licensing agreements, contributes to competitive differentiation. Outsourced manufacturing allows financial focus on R&D and commercialization. However, reliance on third-party manufacturers and the competitive biopharmaceutical landscape present ongoing challenges [S1].

• Dependence on Key Products: INGREZZA and CRENESSITY account for a significant portion of revenue, making the company vulnerable to market changes affecting these products.
• Clinical and Regulatory Risks: Pipeline candidates face inherent risks in clinical trials and regulatory approvals that could delay or prevent commercialization.
• Manufacturing and Supply Chain Risks: Outsourced manufacturing relies on third parties subject to regulatory inspections and supply disruptions.
• Competitive and Pricing Pressure: The biopharmaceutical market is competitive with potential pricing pressures that could impact sales and profitability.
• Operational Costs: Expansion of sales force and infrastructure increases operating expenses, which may affect margins.

• Neurocrine Biosciences is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and commercializing treatments for neurological, psychiatric, endocrine, and immunological disorders [S1].
• The company markets FDA-approved products including INGREZZA (valbenazine) for tardive dyskinesia and chorea associated with Huntington's disease, and CRENESSITY (crinecerfont) for classic congenital adrenal hyperplasia (CAH) [S1].
• INGREZZA net product sales were $2.51 billion in 2025, $2.31 billion in 2024, and $1.84 billion in 2023, representing a significant portion of total net product sales [S1].
• CRENESSITY net product sales were $301.2 million in 2025 during its first full year of launch [S1].
• The company sells INGREZZA exclusively in the U.S. through a limited specialty network including specialty pharmacy providers and distributors, and CRENESSITY through a single specialty pharmacy provider [S1].
• Neurocrine has a specialized U.S. sales force of approximately 600 professionals focused on neurology, psychiatry, long-term care, and rare diseases, with plans to expand the sales teams for INGREZZA and CRENESSITY to enhance commercial reach [S1].
• The company relies on third-party manufacturers for production of its products and candidates, with long-term supply agreements and quality oversight [S1].
• The clinical pipeline includes late-stage candidates osavampator for major depressive disorder and direclidine for schizophrenia, both in Phase 3 clinical programs [S1].
• Early-stage psychiatry programs include muscarinic receptor modulators and next-generation VMAT2 inhibitors aimed at improving treatment adherence and convenience [S1].
• Neurology pipeline focuses on selective modulation of sodium channels and muscarinic receptors for epilepsy and movement disorders, with several candidates in Phase 1 development [S1].
• Endocrinology pipeline includes CRF-1 receptor antagonist CRENESSITY and investigational long-acting CRF-1 antagonist peptide NBIP-01435 for CAH, and CRF-2 receptor agonist NBIP-2118 for obesity and metabolic diseases in early development [S1].
• Recent Q2 2026 financial results show net income of $144.4 million, basic EPS of $1.43, and diluted EPS of $1.39 for the period ending June 30, 2026 [S2].
• Liquidity as of June 30, 2026 includes cash and equivalents of $332.4 million, current assets of $1.6375 billion, current liabilities of $874.5 million, with a current ratio of 1.87 and cash ratio of 0.88 [S2].
• Recent news highlights include a 39% jump in Q2 revenue and raised FY26 INGREZZA sales guidance, portfolio expansion driving growth, and Q2 profit climb [N2][N4][N8].